Stockscreener 앱 받기
0.65
0.75%
-0.0049
시간 외 거래:
.68
0.03
+4.62%
전일 마감가:
$0.6549
열려 있는:
$0.6378
하루 거래량:
631.93K
Relative Volume:
1.52
시가총액:
$3.08M
수익:
-
순이익/손실:
$-11.53M
주가수익비율:
-0.1349
EPS:
-4.82
순현금흐름:
$-11.12M
1주 성능:
-4.69%
1개월 성능:
-26.45%
6개월 성능:
-69.05%
1년 성능:
-72.46%
1일 변동 폭
$0.58
$0.6908
1주일 범위
$0.47
$0.8089
52주 변동 폭
$0.47
$3.305
프로세사 파마슈티컬스 Stock (PCSA) Company Profile
명칭
Processa Pharmaceuticals Inc
전화
443-776-3133
주소
7380 COCA COLA DRIVE, HANOVER
PCSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.65 | 3.08M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
프로세사 파마슈티컬스 Stock (PCSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 개시 | H.C. Wainwright | Buy |
프로세사 파마슈티컬스 주식(PCSA)의 최신 뉴스
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan
Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Processa Pharmaceuticals' chief business officer buys $34,691 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals director David Young buys $99,288 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 By Investing.com - Investing.com UK
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Ulcerated Necrobiosis Lipoidica Market to Reach New Heights - openPR
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa CEO and Board Members Double Down: Major Insider Buying in Latest $5M Deal - StockTitan
Processa Pharmaceuticals stock hits 52-week low at $0.65 By Investing.com - Investing.com South Africa
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance
PROCESSA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K) -June 09, 2021 at 01:17 pm EDT - Marketscreener.com
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.8 - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.8 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why - Defense World
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Gastroparesis Treatment Market Future Business Opportunities - openPR
Trump Media & Technology Group Corp (DJT-Q) QuotePress Release - The Globe and Mail
Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
BCE Inc (BCE-T) QuotePress Release - The Globe and Mail
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Processa Pharmaceuticals stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.85 - Investing.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
U S Antimony Corp (UAMY-A) QuotePress Release - The Globe and Mail
What is HC Wainwright’s Forecast for PCSA FY2024 Earnings? - Defense World
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals stock hits 52-week low at $1.04 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $1.04 - Investing.com India
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Processa Pharmaceuticals stock hits 52-week low at $1.18 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $1.18 By Investing.com - Investing.com UK
프로세사 파마슈티컬스 (PCSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):